Payment overview · 2025
General Payments
$513.38
23 reported records · 12 companies
Healthcare provider profile · identity verified
Thomas Mccullough
Allopathic & Osteopathic Physicians|Internal Medicine · AIKEN, SC · NPI 1093980757
Verified facts
What the public records show
CMS Open Payments records show Thomas Mccullough received $513.38 in general payments during 2025 across 23 reported records.
AstraZeneca Pharmaceuticals LP accounted for 35.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 14 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Mounjaro, Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 62 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 92 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NEXIUM as an associated drug or biological on 464 records involving 299 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Nexium by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 77 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 77 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 50 claims for Trulicity by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 81 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 121 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $183.16 | 35.7% | 8 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $70.77 | 13.8% | 3 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $46.46 | 9.1% | 2 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $42.09 | 8.2% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $29.43 | 5.7% | 1 | 2025 |
| Stryker Corporation | Unresolved — no canonical attribution shown | $28.94 | 5.6% | 1 | 2025 |
| ACADIA Pharmaceuticals Inc | Unresolved — no canonical attribution shown | $22.12 | 4.3% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $19.34 | 3.8% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $19.02 | 3.7% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $17.94 | 3.5% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $17.33 | 3.4% | 1 | 2025 |
| ABIOMED | Unresolved — no canonical attribution shown | $16.78 | 3.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $513.38 | 23 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $103.20 | 3 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $87.96 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $70.77 | 3 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $65.18 | 4 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $42.09 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $29.43 | 1 | 2025 |
Source payment records
|
|||||
| CLOTTRIEVER BOLD CATHETER Normalized: clottriever bold catheter |
Device | Stryker Corporation | $28.94 | 1 | 2025 |
Source payment records
|
|||||
| WATCHMAN FLX Normalized: watchman flx |
Device | Boston Scientific Corporation | $24.88 | 1 | 2025 |
Source payment records
|
|||||
| NUPLAZID Normalized: nuplazid |
Drug | ACADIA Pharmaceuticals Inc | $22.12 | 1 | 2025 |
Source payment records
|
|||||
| WATCHMAN Access System Normalized: watchman access system |
Device | Boston Scientific Corporation | $21.58 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $19.34 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $19.02 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $17.94 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $17.33 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 92 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 77 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 44 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 121 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
62 | 18 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
92 | 17 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | NEXIUM open payments reported associated product |
CMS Open Payments — General Payments 464 supporting records · 299 recipient NPIs · example record 1206134180 |
Nexium · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
77 | 17 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
77 | 17 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
44 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
50 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
81 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
121 | 20 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1436 | 242 |
| Levothyroxine Sodium | Levothyroxine Sodium | 1192 | 192 |
| Amlodipine Besylate | Amlodipine Besylate | 1167 | 205 |
| Pravastatin Sodium | Pravastatin Sodium | 1127 | 176 |
| Omeprazole | Omeprazole | 886 | 133 |
| Valsartan | Valsartan | 755 | 55 |
| Tamsulosin Hcl | Tamsulosin Hcl | 700 | 81 |
| Losartan Potassium | Losartan Potassium | 649 | 150 |
| Gabapentin | Gabapentin | 644 | 93 |
| Clopidogrel | Clopidogrel Bisulfate | 564 | 54 |
| Metoprolol Succinate | Metoprolol Succinate | 562 | 77 |
| Eliquis | Apixaban | 540 | 60 |
| Hydrochlorothiazide | Hydrochlorothiazide | 540 | 121 |
| Meloxicam | Meloxicam | 523 | 106 |
| Famotidine | Famotidine | 513 | 79 |
| Carvedilol | Carvedilol | 512 | 49 |
| Montelukast Sodium | Montelukast Sodium | 473 | 47 |
| Metoprolol Tartrate | Metoprolol Tartrate | 455 | 36 |
| Metformin Hcl | Metformin Hcl | 453 | 95 |
| Pantoprazole Sodium | Pantoprazole Sodium | 437 | 81 |
| Potassium Chloride | Potassium Chloride | 428 | 35 |
| Furosemide | Furosemide | 424 | 65 |
| Duloxetine Hcl | Duloxetine Hcl | 402 | 45 |
| Lisinopril | Lisinopril | 399 | 87 |
| Trazodone Hcl | Trazodone Hcl | 374 | 62 |
| Levetiracetam | Levetiracetam | 300 | 18 |
| Simvastatin | Simvastatin | 290 | 80 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 287 | 75 |
| Sertraline Hcl | Sertraline Hcl | 274 | 43 |
| Allopurinol | Allopurinol | 273 | 57 |
| Celecoxib | Celecoxib | 263 | 47 |
| Spironolactone | Spironolactone | 237 | 27 |
| Alprazolam | Alprazolam | 231 | 44 |
| Glipizide Er | Glipizide | 204 | 47 |
| Chlorthalidone | Chlorthalidone | 201 | 31 |
| Hydralazine Hcl | Hydralazine Hcl | 199 | 16 |
| Bupropion Xl | Bupropion Hcl | 195 | 30 |
| Midodrine Hcl | Midodrine Hcl | 187 | 12 |
| Escitalopram Oxalate | Escitalopram Oxalate | 183 | 26 |
| Finasteride | Finasteride | 183 | 25 |
| Digoxin | Digoxin | 181 | 11 |
| Januvia | Sitagliptin Phosphate | 181 | 31 |
| Lorazepam | Lorazepam | 173 | 33 |
| Clonazepam | Clonazepam | 157 | 21 |
| Pioglitazone Hcl | Pioglitazone Hcl | 154 | 23 |
| Donepezil Hcl | Donepezil Hcl | 151 | 17 |
| Prednisone | Prednisone | 149 | 36 |
| Fluoxetine Hcl | Fluoxetine Hcl | 146 | 12 |
| Tramadol Hcl | Tramadol Hcl | 145 | 37 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 142 | suppressed |
| Tradjenta | Linagliptin | 142 | 13 |
| Citalopram Hbr | Citalopram Hydrobromide | 140 | 16 |
| Amiodarone Hcl | Amiodarone Hcl | 139 | 13 |
| Doxazosin Mesylate | Doxazosin Mesylate | 131 | 14 |
| Sevelamer Carbonate | Sevelamer Carbonate | 130 | suppressed |
| Aripiprazole | Aripiprazole | 129 | 12 |
| Ropinirole Hcl | Ropinirole Hcl | 129 | 13 |
| Metformin Hcl Er | Metformin Hcl | 127 | 34 |
| Buspirone Hcl | Buspirone Hcl | 125 | 21 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 122 | 27 |
| Ozempic | Semaglutide | 121 | 20 |
| Zolpidem Tartrate | Zolpidem Tartrate | 113 | 24 |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 104 | suppressed |
| Mirtazapine | Mirtazapine | 99 | 19 |
| Fluticasone Propionate | Fluticasone Propionate | 98 | 29 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 98 | 18 |
| Risperidone | Risperidone | 94 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 92 | 17 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 91 | 22 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 87 | 36 |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 87 | 12 |
| Azithromycin | Azithromycin | 84 | 57 |
| Quetiapine Fumarate | Quetiapine Fumarate | 82 | 16 |
| Sucralfate | Sucralfate | 82 | 14 |
| Diazepam | Diazepam | 81 | 15 |
| Entresto | Sacubitril/Valsartan | 81 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 81 | 13 |
| Alendronate Sodium | Alendronate Sodium | 79 | 22 |
| Ondansetron Hcl | Ondansetron Hcl | 78 | 33 |
| Jardiance | Empagliflozin | 77 | 17 |
| Paroxetine Hcl | Paroxetine Hcl | 77 | suppressed |
| Baclofen | Baclofen | 76 | suppressed |
| Memantine Hcl | Memantine Hcl | 74 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 73 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 71 | 16 |
| Atenolol | Atenolol | 70 | 18 |
| Ezetimibe | Ezetimibe | 67 | 12 |
| Pregabalin | Pregabalin | 67 | 16 |
| Primidone | Primidone | 67 | suppressed |
| Torsemide | Torsemide | 67 | 17 |
| Amitriptyline Hcl | Amitriptyline Hcl | 65 | 12 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 64 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 62 | suppressed |
| Synthroid | Levothyroxine Sodium | 62 | 18 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 61 | 14 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 60 | 20 |
| Oxcarbazepine | Oxcarbazepine | 60 | suppressed |
| Novolog Flexpen | Insulin Aspart | 59 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 57 | 18 |
| Clindamycin Hcl | Clindamycin Hcl | 56 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 56 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 56 | suppressed |
| Nifedipine Er | Nifedipine | 56 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 54 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 54 | 11 |
| Flecainide Acetate | Flecainide Acetate | 53 | suppressed |
| Ranolazine Er | Ranolazine | 53 | suppressed |
| Isosorbide Dinit-Hydralazine | Isosorbide Dinit/Hydralazine | 52 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 52 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 52 | suppressed |
| Amantadine | Amantadine Hcl | 51 | suppressed |
| Myrbetriq | Mirabegron | 51 | 11 |
| Oxybutynin Chloride | Oxybutynin Chloride | 50 | suppressed |
| Trulicity | Dulaglutide | 50 | suppressed |
| Xarelto | Rivaroxaban | 50 | suppressed |
| Movantik | Naloxegol Oxalate | 49 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 47 | 44 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 47 | 33 |
| Trospium Chloride | Trospium Chloride | 47 | suppressed |
| Fenofibrate | Fenofibrate | 46 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 45 | 39 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 44 | suppressed |
| Mounjaro | Tirzepatide | 44 | suppressed |
| Tiadylt Er | Diltiazem Hcl | 44 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 42 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 41 | 11 |
| Metoclopramide Hcl | Metoclopramide Hcl | 41 | suppressed |
| Bumetanide | Bumetanide | 39 | suppressed |
| Lamotrigine | Lamotrigine | 39 | suppressed |
| Ramipril | Ramipril | 39 | 12 |
| Paxlovid | Nirmatrelvir/Ritonavir | 38 | 38 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 37 | 13 |
| Ibandronate Sodium | Ibandronate Sodium | 37 | suppressed |
| Irbesartan | Irbesartan | 35 | suppressed |
| Latanoprost | Latanoprost | 35 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 34 | suppressed |
| Glimepiride | Glimepiride | 34 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 34 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 33 | 11 |
| Meclizine Hcl | Meclizine Hcl | 33 | 14 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 32 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 32 | suppressed |
| Cephalexin | Cephalexin | 32 | 20 |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 32 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 31 | suppressed |
| Amoxicillin | Amoxicillin | 30 | 27 |
| Folic Acid | Folic Acid | 30 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 30 | suppressed |
| Theophylline Er | Theophylline Anhydrous | 30 | suppressed |
| Methylprednisolone | Methylprednisolone | 29 | 26 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 29 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 28 | suppressed |
| Estradiol | Estradiol | 28 | 12 |
| Temazepam | Temazepam | 28 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 28 | 16 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 28 | suppressed |
| Verapamil Er | Verapamil Hcl | 28 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 27 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 27 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 26 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 26 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 26 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 24 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 23 | suppressed |
| Lubiprostone | Lubiprostone | 23 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 23 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 22 | suppressed |
| Ethambutol Hcl | Ethambutol Hcl | 22 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 22 | suppressed |
| Rifampin | Rifampin | 22 | suppressed |
| Roflumilast | Roflumilast | 21 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 20 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 20 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 20 | suppressed |
| Lovastatin | Lovastatin | 20 | suppressed |
| Methocarbamol | Methocarbamol | 20 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 19 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 19 | 11 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 18 | suppressed |
| Fluconazole | Fluconazole | 18 | 14 |
| Klor-Con M20 | Potassium Chloride | 18 | suppressed |
| Brilinta | Ticagrelor | 17 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 17 | suppressed |
| Spironolactone-Hctz | Spironolact/Hydrochlorothiazid | 17 | suppressed |
| Cefazolin Sodium-Dextrose | Cefazolin Sodium/Dextrose,iso | 16 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 16 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 16 | suppressed |
| Glipizide | Glipizide | 16 | suppressed |
| Ibuprofen | Ibuprofen | 15 | suppressed |
| Levemir Flexpen | Insulin Detemir | 15 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 15 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 15 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 14 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 14 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 14 | suppressed |
| Nitroglycerin | Nitroglycerin | 14 | suppressed |
| Eszopiclone | Eszopiclone | 13 | suppressed |
| Hydrocortisone | Hydrocortisone | 13 | suppressed |
| Nitroglycerin Patch | Nitroglycerin | 13 | suppressed |
| Rexulti | Brexpiprazole | 13 | suppressed |
| Testosterone | Testosterone | 13 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Belsomra | Suvorexant | 12 | suppressed |
| Biktarvy | Bictegrav/Emtricit/Tenofov Ala | 12 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 12 | suppressed |
| Humulin N | Insulin Nph Human Isophane | 12 | suppressed |
| Methotrexate | Methotrexate Sodium | 12 | suppressed |
| Nexium | Esomeprazole Magnesium | 12 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 12 | suppressed |
| Nystatin | Nystatin | 12 | suppressed |
| Ondansetron Odt | Ondansetron | 12 | suppressed |
| Tamoxifen Citrate | Tamoxifen Citrate | 12 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Cilostazol | Cilostazol | 11 | suppressed |
| Cimetidine | Cimetidine | 11 | suppressed |
| Colchicine | Colchicine | 11 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 11 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 11 | suppressed |
| Mesalamine | Mesalamine | 11 | suppressed |
| Topiramate | Topiramate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $513.38 · 23 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, BREZTRI, CLOTTRIEVER BOLD CATHETER, FARXIGA, FREESTYLE LIBRE 3, JARDIANCE, LEQVIO, MOUNJARO, NUPLAZID, Ozempic, The Cologuard Plus Collection Kit, UBRELVY, WATCHMAN Access System, WATCHMAN FLX | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error